

Certificate of Analysis for NR-55585

Klebsiella pneumoniae, Strain MRSN 669510

Catalog No. NR-55585

This reagent is the tangible property of the U.S. Government.

Product Description:

Klebsiella pneumoniae (K. pneumoniae), strain MRSN 669510 was isolated in 2018 from a human respiratory sample in Europe as part of a global surveillance program. NR-55585 was deposited as a multidrug-resistant (MDR) strain, sensitive to amikacin, ciprofloxacin, gentamicin, levofloxacin, tigecycline and tetracycline, intermediately resistant to aztreonam, ertapenem and tobramycin, and resistant to ampicillin/sulbactam, cefepime, ceftazidime, ceftazidime/avibactam, ceftolozane/tazobactam, ceftriaxone, imipenem, meropenem, piperacillin/tazobactam and trimethoprim/sulfamethoxazole. NR-55585 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. The material from the initial growth was added to Tryptic Soy broth, which was grown for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70051607 Manufacturing Date: 07APR2022

BEI Resources is committed to ensuring digital accessibility for people with disabilities. This Certificate of Analysis contains complex tables and may not be fully accessible. Please let us know if you encounter accessibility barriers and a fully accessible document will be provided: E-mail: Contact@BEIResources.org. We try to respond to feedback within 24 hours.

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology	Report results	Circular, convex, entire, smooth, mucoid and cream
Motility (wet mount)	Report results	Non-motile
VITEK® 2 (GN card)	K. pneumoniae (≥ 89%)	K. pneumoniae (99%)
Antibiotic Susceptibility Profile ^{1,2}		
Amikacin	Sensitive	Sensitive (≤ 2 µg/mL)
Ampicillin/sulbactam	Resistant	Resistant (≥ 32 µg/mL)
Aztreonam	Intermediate	Intermediate (8 to 12 µg/mL)
Cefepime	Resistant	Resistant (≥ 64 µg/mL)
Ceftazidime	Resistant	Resistant (≥ 64 µg/mL)
Ceftazidime/avibactam	Resistant	Resistant (≥ 256 µg/mL)
Ceftolozane/tazobactam	Resistant	Resistant (≥ 256 µg/mL)
Ceftriaxone	Resistant	Resistant (≥ 64 µg/mL)
Ciprofloxacin	Sensitive	Sensitive (0.064 to 0.094 µg/mL)
Ertapenem	Intermediate	Sensitive (0.19 to 0.25 μg/mL) ³
Gentamicin	Sensitive	Sensitive (≤ 1 µg/mL)
Imipenem	Resistant	Resistant (4 µg/mL)
Levofloxacin	Sensitive	Sensitive (≤ 0.12 μg/mL)
Meropenem	Resistant	Resistant (≥ 16 µg/mL)
Piperacillin/tazobactam	Resistant	Resistant (≥ 128 µg/mL)
Tetracycline	Sensitive	Sensitive (≤ 1 µg/mL)
Tigecycline	Sensitive	Sensitive (1 µg/mL) ⁴
Tobramycin	Intermediate	Intermediate (8 µg/mL)
Trimethoprim/sulfamethoxazole	Resistant	Resistant (≥ 320 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (~ 1470 base pairs)	≥ 99% sequence identity to K. pneumoniae, strain MRSN 669510 (GenBank: JAGYCA010000117.1)	99.7% sequence identity to K. pneumoniae, strain MRSN 669510 (GenBank: JAGYCA010000117.1)

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898



Certificate of Analysis for NR-55585

TEST	SPECIFICATIONS	RESULTS
Purity 7 days at 37°C in an aerobic atmosphere with and without 5% CO ₂ on Tryptic Soy agar	ļ -	ccted Growth consistent with expected colony morphology
Viability	Growth	Growth

¹Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

/Sonia Bjorum Brower/ Sonia Bjorum Brower

14 JUN 2022

Lead Technical Writer or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898

²Antibiotic susceptibility was tested using a combination of bioMérieux VITEK®2 GN74 and ETEST®.

³K. pneumoniae, strain MRSN 669510 was deposited as intermediately resistant to ertapenem, but showed a MIC of 0.19 to 0.25 μg per mL (interpreted as sensitive) for this antibiotic during QC testing. Testing was performed in duplicate.

⁴MIC Interpretation Guideline: EUCAST Version 8.0 (2018)